#United States #financial results #Abbott Park #Abbott Laboratories #EPS Guidance

Abbott's Second Quarter 2026 Financial Performance Overview

Abbott (NYSE: ABT) has updated its investors on its financial performance for the second quarter that ended on June 30, 2026. The results signal a positive trajectory for the company, demonstrating significant sales growth, robust earnings, and improved guidance for the remainder of the year.

Sales Growth and Earnings

In the second quarter, Abbott reported a notable 13.0% increase in total sales, alongside a 4.8% rise in comparable sales. This growth reflects not only the strength of Abbott's product offerings but also the successful integration of Exact Sciences, a cancer diagnostics company acquired in March 2026. The company's total reported sales reached $12.593 billion for the quarter.

Abbott's GAAP diluted earnings per share (EPS) for the quarter was $0.53, with an adjusted diluted EPS of $1.31, excluding certain specified items. The latter figure signifies a 4.0% increase from the prior year’s corresponding period. Notably, Abbott has also revised its expectations for the full year 2026, raising its adjusted diluted EPS forecast to a range between $5.45 and $5.60. This is an increase from the previous estimate of $5.38 to $5.58.

Business Unit Highlights

Sales growth was driven across multiple sectors:

• - Nutrition sales totaled $2.144 billion, a slight decrease of 3.1% due to lower volumes compared to the previous year as well as strategic pricing changes affecting performance. However, the Nutrition sector is expected to rebound with newly launched products contributing positively going forward.
• - Diagnostics saw impressive sales growth, retrieving $3.092 billion, which represents a 42.3% increase year-over-year. Core Laboratory Diagnostics expanded, especially in the U.S. market, with continued growth in cancer diagnostics, underscored by strong adoption of Cologuard.
• - For Medical Devices, Abbott reported sales of $5.853 billion, up 9.0%, indicating solid performance across major product categories, particularly in Electrophysiology and Diabetes Care, where continuous glucose monitors experienced a robust surge in demand.

Investments and Developments

Abbott continues to focus on innovation, completing enrollment in its pivotal TECTONIC trial evaluating coronary intravascular lithotripsy for patients with severe calcifications. This commitment to R&D, coupled with recent regulatory achievements like securing CE Mark for the Libre® Duo biowearable sensor, exemplifies Abbott's dedication to advancing healthcare technologies.

Additionally, Abbott declared a dividend of $0.63 per share on June 12, 2026, marking its 410th consecutive quarterly dividend. This reflects Abbott’s long-standing commitment to returning value to shareholders, having increased its dividend payouts annually for over five decades.

As CEO Robert B. Ford noted, “Our second-quarter results reflect the momentum we are building. We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year.”

Conclusion

Abbott’s second-quarter performance firmly establishes the company’s growth trajectory and its strategic moves in enhancing shareholder value. The raised EPS guidance coupled with robust sales across key segments presents a positive outlook for the remainder of 2026. As Abbott continues to innovate and expand, stakeholders can look forward to further advancements in healthcare solutions and sustained financial performance.

For in-depth information about Abbott's performance and to stay updated on future announcements, please visit Abbott's Investor Relations.